Bennett WL, Maruthur NM, Singh S, et al.Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drugcombinations. Ann Intern Med 011;154:602–613

Bergenstal RM, Klonoff DC, Garg SK, et al.;ASPIRE In-Home Study Group. Threshold based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224–232

Diabetes Atlas, 6th edition, International Diabetes Federation, 2013.

Egede LE, Zheng D, Simpson K: Cormorbid depression is associated with increase health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25(3):464-470.

Ekström N, Schiöler L, Svensson A-M, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open2012;2:e001076.

Fong, D., et al. “Diabetic Retinopathy” Diabetes Care, Volume 26, Supplement 1, January 2003, pp. 99 – 102

Gross, J., et al. “ Diabetic Nephropathy: Diagnosis, Prevention, and Treatment” Diabetes Care, Volume 28, Number 1, January 2005. pp. 164-176

Haynes RD: A critical review of determinants of patient compliance and therapeutic regimens, in Sackett DL, Haynes RD (eds): Compliance with Therapeutic Regimens. Johns Hopkins University Press, 1976.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554–559

Inzucchi SE, Bergenstal RM, Buse JB, et al.;American Diabetes Association (ADA);European Association for the Study ofDiabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403

Lam, S. See, S. “Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.” Cardiol Rev. 2006 Jul-Aug;14(4):205-11.

Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010 Sep 1;33(9):727-40.

Lindstrom J, Eriksson JG, Valle TT, et al: Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial. J Am Soc Nephrol 2003;14(7 suppl 2):S108-S113.

Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011 Jun;34(6):1431-7.

Lu WR, Defilippi J, Braun A. Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother. 2013 Nov;47(11):1488-97.

Mensing, RN, MA, CDE, et. al, National standards for diabetes self-management education. Diabetes Care. 2006 Jan;29 Suppl 1:S78-85.

Molitch ME, Fujimoto W, Hamman RF, et al: The Diabetes Prevention Program and its global implications. J Am Soc Nephrol 2003;14(7 suppl 2):S103-S107.

Nathan DM et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–759.

National Diabetes Fact Sheet, 2011.

Norris SL, Engelgau MM, Narayan KM: Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 24:561–587, 2001

Ogrinc, G., Headrick, L. A framework for teaching medical students and residents about practice-based learning and improvement, synthesized from a literature review. Acad Med. 2003 Jul;78(7):748-56.

Peterson K, Silverstein J, Kaufman F, Warren-Boulton E. Management of type 2 diabetes in youth: an update. Am Fam Physician. 2007 Sep 1;76(5):658-64.

Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013 Jan-Feb;26(1):55-60.

Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. 2010. The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis. Diabetes Care, 33(8), 1859-1864.

Spann, S., et al. “Management of Type 2 Diabetes in Primary Care Setting: A Practice Based Research Network Study.” Annals of Fam Med 2006 Vol 4 No. 1, 23-31

Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321(7258):405-12.

<< Strategies for Improving Diabetes Care: Practice Based Learning